Deutsche Bank’s VistaGen Therapeutics VTGN Stock Holding History

Deutsche Bank’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76K	Buy	+12,000	New	+$7.24K	﹤0.01%	3650
2023 Q3	–	Sell	-4,393	Closed	-$8.21K	–	3827
2023 Q2	$8.21K	Sell	4,393 -4,008	-48%	-$14K	﹤0.01%	3667
2023 Q1	$31.5K	Buy	8,401 +5,484	+188%	+$28.8K	﹤0.01%	3645
2022 Q4	$9.01K	Sell	2,917 -8,057	-73%	-$30.3K	﹤0.01%	3861
2022 Q3	$50K	Buy	10,974 +7,667	+232%	+$76K	﹤0.01%	3590
2022 Q2	$87K	Sell	3,307 -443	-12%	-$15.6K	﹤0.01%	3579
2022 Q1	$140K	Sell	3,750 -417	-10%	-$18.2K	﹤0.01%	3448
2021 Q4	$244K	Buy	4,167 +207	+5%	+$13.5K	﹤0.01%	3281
2021 Q3	$326K	Sell	3,960 -2,261	-36%	-$196K	﹤0.01%	3302
2021 Q2	$588K	Buy	+6,221	New	+$461K	﹤0.01%	3114

Other funds holding VTGN

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Deutsche Bank's VTGN Position: Q2 2026 in Review

Deutsche Bank opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 12,000 shares worth $2.76K. The stake represents ﹤0.01% of the portfolio and ranks #3650 among its holdings. This is a return to the name: Deutsche Bank previously reported a position in VTGN as recently as Q2 2023.

Deutsche Bank first reported a position in VTGN in Q2 2021 and has held it in 10 quarters since. The position peaked at $588K in Q2 2021. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

Deutsche Bank held 12,000 shares of VistaGen Therapeutics worth $2.76K as of Q2 2026.
VistaGen Therapeutics was a new Deutsche Bank position in Q2 2026.
VistaGen Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3650 holding.
Deutsche Bank first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 10 quarters since.
Deutsche Bank's VistaGen Therapeutics position peaked at $588K in Q2 2021.
48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.